Nextcure, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
August 05, 2021 at 04:05 pm EDT
Share
NextCure, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported nil revenue. Loss from operations was $17,952,000 against $15,801,000 a year ago. Net loss was $17,987,000 against $14,508,000 a year ago. Net loss per common share, basic and diluted was $0.65 against $0.53 a year ago.
For the six months, the company reported nil revenue. Loss from operations was $35,186,000 against $7,589,000 a year ago. Net loss was $34,520,000 against $4,775,000 a year ago. Net loss per common share, basic and diluted was $1.25 against $0.17 a year ago.
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
NEXTCURE, INC. 
